StockData

ADC Therapeutics vs Verastem

ADCT and VSTM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ADCT and VSTM compare

Verastem is the larger company, worth 4.4 times as much as ADC Therapeutics ($697M against $160M).

ADC Therapeutics keeps more of each dollar of sales as profit, with a net margin of −95.7% compared with −232% at Verastem.

ADC Therapeutics scores higher on the StockData Score (4 against 3 for Verastem), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricADCTVSTM
Size and price
Market cap$160M$697M
Share price$1.25$7.70
Change, 1 year−69.1%−5.1%
Change, 5 years−94.4%−76.1%
Beta (5Y)2.952.60
Employees188102
StockData Score
Total score4 (better)3
Valuation score1 (better)0
Growth score11
Performance score11
Health score11
Dividend score00
Valuation
P/S1.9× (better)8.0×
P/B–14.0×
FCF yield−63.0%–
Growth
Revenue growth (TTM)12.8%–
Revenue growth, 5Y average–−19.0%
Profitability
Operating margin−97.7% (better)−183%
Net margin−95.7% (better)−232%
FCF margin−118%–
Return on equity–−471%
Financial health
Interest coverage−1.6× (better)−108.3×
Current ratio3.05 (better)2.25
Altman Z-score−9.16−7.27 (better)
Piotroski F-score6 (better)4
Dividends and buybacks
Buyback yield−26.7%–
Shareholder yield−26.7%0.00% (better)
Ownership
Held by institutions72.9%109%
Held by insiders42.8%1.8%
Insider net buying, 12 months−$19.6M−$816K (better)
Short interest, % of float8.8%22.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.